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Received November 22, 2015; accepted February 1, 2016AbstractBackground: This study aimed to evaluate the association between complications and clinical parameters with obesity in 273 women who have
undergone abdominal myomectomy during the study period.
Methods: The patients were classified into two groups according to body mass index (BMI) (30 kg/m2 and >30 kg/m2). Demographic,
preoperative and postoperative clinical parameters were evaluated.
Results: Demographic, preoperative and postoperative clinical parameters were evaluated. The results showed statistically significant differences
between the obese and non-obese groups in terms of age, gravidity, diameter of fibroid (DOF), postoperative hemoglobin, duration of hospital
stay, and complications. Patients in the obese group had greater DOF and complications such as hemorrhage, postoperative fever, wound
infection and ileus ( p < 0.05).
Conclusion: Based on our results, we conclude that obesity adversely affects the clinical outcomes of patients who undergo abdominal myo-
mectomy.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Uterine fibroids (UF) are the most common neoplasms of
the uterus, with approximately 25e30% of women suffering
from the disorder.1 Among these women, 50% are symptom-
atic and present with complaints, such as vaginal bleeding,
pelvic pain, pressure sensation, severe anemia, and urethral
obstruction.2,3
Myomectomy is performed mainly in women who desire to
protect their fertility.4 Although new techniques developed forConflicts of interest: The authors declare that they have no conflicts of interest
related to the subject matter or materials discussed in this article.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).myomectomy are used widely with lower ratios of complica-
tions (e.g., decreased hospitalization, less blood loss, fewer
postoperative adhesions, and shorter recovery), most myo-
mectomies are still done via laparotomy.5
In regard to the association of obesity with the development
of UFs, the risk of fibroids developing in women weighing
70 kg is three times greater than in women weighing 50 kg.6
Independent of body mass index (BMI), central obesity
(excess fat in the upper trunk region) is associated with
changed estrogen metabolism, insulin resistance, hyper-
insulinemia, and decreases in sex hormone-binding globulin
levels, which results in the promotion of myometrial smooth
muscle cell proliferation.7 All over the world, a minimally
invasive approach, including laparoscopic and robotic myo-
mectomy, is used increasingly in the management of UFs.8
Because these approaches require skilled clinicians insevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
The demographic and clinical features between the groups.
Variables Patients with
BMI 30 (n¼183)
Patients with
BMI >30 (n¼90)
p
Age (years) 36.0 ± 4.0 41.7 ± 4.1 <0.001
Gravidity (minemax) 2 (1e4) 3 (1e5) <0.001
Parity (minemax) 1 (1e4) 2 (1e5) <0.001
Abortion 0.0 ± 1.0 1.0 ± 1.0 <0.001
BMI (kg/m2) 27.0 ± 2.2 31.9 ± 1.5 <0.001
DOF (cm) 6.0 ± 2.0 7.0 ± 2.0 <0.001
Preoperative Hb (g/dL) 12.7 ± 1.3 12.4 ± 1.3 0.052
Postoperative Hb (g/dL) 11.1 ± 1.6 10.4 ± 1.6 0.002
Urea (mg/dL) 26.3 ± 7.6 25.7 ± 7.2 0.546
Creatinine (mg/dL) 0.7 ± 0.1 0.7 ± 0.1 0.439
AST (U/L) 18.0 ± 3.7 19.5 ± 6.7 0.234
ALT (U/L) 15.1 ± 6.0 17.6 ± 10.2 0.053
Platelets (103/mL) 271.5 ± 89.8 283.7 ± 84.2 0.261
WBC (103/mL) 7.1 ± 2.6 7.1 ± 2.7 0.391
AFP (mg/L) 2.1 ± 1.8 2.4 ± 1.6 0.075
NLR 2.2 ± 1.1 2.0 ± 1.0 0.187
DHS (days) 2.8 ± 1.0 3.3 ± 1.8 0.001
p < 0.05 is considered statistically significant.
AFP ¼ alpha-fetoprotein; ALT ¼ alanine transaminase; AST ¼ aspartate
transaminase; BMI ¼ body mass index; DHS ¼ duration of hospital stay;
DOF ¼ diameter of fibroid; Hb ¼ hemoglobin; NLR ¼ neutrophil/lymphocyte
ratio; WBC ¼ white blood cell.
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laparotomy in many institutions.9
In this study, we evaluated the association between obesity
and clinical parameters in women who had undergone
abdominal myomectomy.
2. Methods
This retrospective study was conducted from January 2009
to December 2012 in the Zekai Tahir Burak Women's Health
Education and Research Hospital, Ankara, Turkey. This is a
tertiary teaching and research hospital in the middle region of
Turkey. The data was collected from the hospital database and
patient notes; a descriptive analysis was performed on the
patients' characteristics and demographics. The ethics com-
mittee of the hospital approved the study. Due to the retro-
spective design of the study, we did not obtain informed
consent from the subjects.
The analyses took into account the factors of age, BMI
[weight, kg/(height, m)2], gravidity, parity, diameter of the
fibroid (DOF), preoperative and postoperative hemoglobin
levels, white blood cell count, thrombocyte count, neu-
trophilelymphocyte ratio (NLR), CA125 levels, duration of
postoperative hospital stay, and postoperative complications
(wound infections or dehiscence).
The diameter and location of the fibroids were determined
preoperatively by ultrasonography. After taking the patient's
history, including the obstetrical and gynecological history, an
abdominal myomectomy was performed. The surgical in-
dications were categorized into symptoms of bleeding, pain or
pressure, fertility, and other. The surgical technique was as
follows: Pfannenstiel incision or mini-laparotomy was per-
formed on all patients. After the peritoneal cavity was opened,
the pelvic organs and upper abdomen were explored, and a
vertical incision was made through the uterine wall above the
fibroids, using a coagulating or cutting electrode. The UF was
then fixed with a towel clamp, and the cleavage plane between
the fibroid and normal myometrium was dissected using either
a finger or a mosquito clamp. The fibroids were removed, and
the remaining cavity was repaired by continuous suturation.10
3. Statistics
Statistical analyses were carried out using SPSS 15.0, the
statistical software package for Windows (SPSS Inc., Chicago,
IL, USA). The normal distribution of the data was assessed
using the KolmogoroveSmirnov test. Continuous and nor-
mally distributed variables were presented as
means ± standard deviations, and intragroup differences were
investigated using the Student t-test. Continuous variables
with non-normal distribution were expressed as medians
(minimumemaximum), and differences between variables
were analyzed using the ManneWhitney U test. Categorical
variables were expressed in percentages. The sample size was
determined according to the results of the central limit theo-
rem, which indicated that we needed at least 30 individuals in
each subgroup.11 Differences between categorical data wereevaluated using the Chi-square (c2) test. Logistic regression
method was used to evaluate the risk factors for early and late
complications in women undergoing abdominal myomectomy
after adjusting for age. Two-sided p values were considered
statistically significant at p < 0.05.
4. Results
During the study period, 273 patients underwent abdominal
myomectomy at the current clinic. The mean age of the pa-
tients was 37.9 ± 5.7 years, and their mean BMI was
28.9 ± 3.0 kg/m2. The median numbers of gravidity, parity,
and abortion were 2 (0e8), 0 (0e4) and 0 (0e6), respectively.
Forty-three (19.4%) patients had previously undergone at least
one major abdominal surgery.
The patients were divided into two groups according to
BMI (30 kg/m2 and >30 kg/m2). One hundred and eighty
three patients had a BMI of 30 kg/m2 and 90 patients had a
BMI of >30 kg/m2. The former, BMI >30 kg/m2, indicated
obesity. Table 1 summarizes the demographic and clinical
differences between the groups. The mean age, gravidity,
parity, abortion, DOF, postoperative hemoglobin levels, dura-
tion of hospital stay (DHS) and postoperative complications
were statistically significantly different between the groups
( p < 0.05). The correlation analysis found a correlation among
BMI and age, gravidity, DOF, preoperative hemoglobin,
postoperative hemoglobin, the number of erythrocyte sus-
pension transfused and DHS (Table 2). The surgical in-
dications for the majority of patients were menometrorrhagia
and pelvic pressure. Place of fibroid (POF) and ABO blood
groups did not differ between the two groups ( p > 0.05). Early
and late complications were more common in the obese group.
Table 2
Correlation between BMI and demographic and clinical characteristics of the
patients.
Variables CC p
Age 0.484 0.001
Gravidity 0.248 0.001
Parity 0.212 0.001
Abortion 0.150 0.013
DOF 0.239 0.001
Preoperative Hb 0.127 0.036
Postoperative Hb 0.188 0.002
Postoperative gravidity 0.230 0.001
Postoperative abortion 0.150 0.013
Urea 0.020 0.742
Creatinine 0.043 0.483
AST 0.072 0.235
ALT 0.123 0.043
Platelets 0.098 0.107
WBC 0.052 0.391
CA125 0.032 0.599
CA19.9 0.030 0.622
AFP 0.108 0.075
NLR 0.080 0.188
Es Tx 0.131 0.030
DHS 0.211 0.001
Postoperative complication 0.187 0.002
p < 0.05 is considered statistically significant.
AFP ¼ alpha-fetoprotein; ALT ¼ alanine transaminase; AST ¼ aspartate
transaminase; CC ¼ correlation coefficient; DHS ¼ duration of hospital stay;
DOF ¼ diameter of fibroid; Es Tx ¼ erythrocyte suspension transfusion;
Hb ¼ hemoglobin; NLR ¼ neutrophil/lymphocyte ratio; WBC ¼ white blood
cell.
Table 3
Comparison of surgery indication, place of fibroid and complications between
groups.
Variables Patients with
BMI 30, n (%)
Patients with
BMI >30, n (%)
p
Indication for surgery
Pain 57 (31.2) 16 (17.8) 0.013
Infertility 20 (10.9) 8 (8.9)
Menometrorrhagia 51 (27.9) 39 (43.3)
Malignancy suspected 1 (0.5) 1 (1.1)
Pelvic pressure 54 (29.5) 26 (28.9)
Total 183 (100) 90 (100)
POF
Subserosal 47 (25.7) 16 (17.8) 0.337
Submucosal 3 (1.6) 2 (2.2)
Intramural 133 (72.7) 72 (80)
Total
Early complication
Hemorrhage 9 (64.4) 10 (71.4) 0.046
Bowel injury 1 (7.1) 0
PO fever 2 (14.3) 4 (28.6)
Hysterectomy 1 (7.1) 0
Hematoma 1 (7.1) 0
Total 14 (100) 14 (100)
Late complication
Wound Infection 0 11 (45.8) <0.001
Dehiscence 1 (50) 1 (4.2)
Ileus 1 (50) 12 (50)
Total 2 (100) 24 (100)
Es Tx (units)
0 175 (95.6) 80 (88.9) 0.142
1 8 (4.4) 10 (11.1)
Total 183 (100) 90 (100)
Blood group
ARHþ 64 (34.5) 27 (30) 0.430
BRHþ 31 (17.0) 23 (25.6)
ORHþ 52 (28.5) 22 (24.5)
ABRHþ 3 (1.6) 4 (4.4)
ARHe 8 (4.5) 1 (1.1)
BRHe 15 (8.3) 8 (8.9)
ORHe 9 (5.0) 4 (4.4)
ABRHe 1 (0.6) 1 (1.1)
Total 183 (100) 90 (100)
Es Tx ¼ erythrocyte suspension transfusion; PO ¼ postoperative; POF ¼ place
of fibroid.
Data are presented as n (%). Pearson Chi-square test and Fisher's exact test
were used. p < 0.05 is considered statistically significant.
Table 4
Logistic regression model for risk factors of early and late complications of
myomectomy.
Outcome: complication SE Wald P OR 95% CI
DOF 0.114 0.832 0.362 1.109 0.888e1.386
Nulliparity 0.434 0.015 0.904 1.054 0.450e2.469
CA-125 0.010 6.541 0.011 1.025 1.006e1.044
Nonsubserosal 0.677 6.833 0.009 5.875 1.557e22.160
PAS 0.459 0.004 0.947 1.031 0.419e2.537
BMI 0.087 17.787 0.000 1.446 1.218e1.717
p < 0.05 is considered statistically significant.
BMI ¼ body mass index; DOF ¼ diameter of fibroid; PAS ¼ previously
abdominal surgery.
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suspension transfusion occurred in eight patients with 20 U in
the non-obese group and in 10 patients with 43 U in the obese
group (Table 3).
Logistic regressionmethod demonstrated that BMI, POF, and
preoperative serum CA-125 levels were found to be risk factors
for early and late complications with odds ratios (95% confi-
dence interval) as: 1.446 (1.218e1.717), 5.875 (1.557e22.160)
and 1.025 (1.006e1.044), respectively (Table 4).
5. Discussion
In this study, we aimed to evaluate the association between
BMI and clinical parameters in 273 women who underwent
abdominal myomectomy. We found that obesity adversely
affected the length of hospital stay and complications such as
hemorrhage, postoperative fever, wound infection and ileus in
patients who underwent abdominal myomectomy. UFs are the
most common benign gynecological tumors in women of repro-
ductive age. Although they can cause significant health concerns,
the etiology of these neoplasms is not yet understood.12 Experi-
mental and epidemiological studies have established that ovarian
steroid hormones play an essential role in the pathogenesis of this
disease. Specifically, the growthof uterine fibroids depends on the
ovarian hormones, estrogen and progesterone.
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BMI and UF. Some studies have demonstrated an increased risk
of UF with increasing BMI,13,14,15 while others have not.7,16,17
However, it is generally accepted that obesity is an important
risk factor for UF, and increased BMI increases the risk of UF
occurrence. It has been reported that the risk of development of
UF increases by 21% with every increase of 10 kg in body
weight.7,18 However, the underlying mechanism between this
association, as well as the interaction between adipose cells and
uterine fibroid cells, has not yet been well established.
In our study, we found that the DOF was larger in obese
women than in non-obese women. The BMI reflects the ab-
solute measurement of body fat composition.19 It may affect
the development of UF through changes in the steroid hor-
mone metabolism.20 An inverse association between BMI and
circulating levels of sex hormone-binding globulin has been
shown. Once the amount of sex hormone-binding globulin
decreases, the proportion of free estrogen, or the fraction
available for biological activity, may increase.7,21,22 Obesity
also induces the hydroxylation of estrone to estriol. The
increased levels of estriol then influence development of
UF through the direct promotion of myometrial smooth
muscle cell proliferation, as well as the enlargement of UF.7,23
It has been documented that central obesity is positively
associated with age and parity,24,25 as we found in our study.
BMI is associated with the risk of complications after most
surgical procedures. Previous studies have shown that obesity
may increase the risk of bleeding during surgery requiring a
blood transfusion,26 the length of hospital stay,27 and post-
operative complications, such as surgery-related infections.28
These associations can be explained by larger wound sur-
faces, deeper subcutaneous adipose tissue, and greater DOF,
which may cause both a longer amount of time needed to
reach the abdominal cavity and an increased amount of
bleeding, impairing wound healing and causing a high rate of
infectious agent exposure leading to wound infections.
Another interesting finding of this study was the association
between BMI and serum alpha fetoprotein (AFP) levels, which
may indicate an important health problem. AFP is a fetal
glycoprotein produced by the yolk sac and fetal liver, and it
decreases rapidly after childbirth.29 It increases mainly
because of liver pathologies (steatosis, hepatitis, cirrhosis,
carcinoma, etc.) in which the hepatocyteehepatocyte in-
teractions are altered and the normal architectural arrange-
ments are lost. With increasing BMI, obesity-related
inflammation is highly likely to cause hepatic steatosis,
resulting in increased levels of serum AFP.30
Minimally invasive approaches have found more clinical
usage in the management of UFs. Previous studies reported
that, even in morbidly obese, laparoscopic myomectomy can
be performed safely and is the preferred surgical method in
obese patients.31,32 The limitation of our study is the lack of
comparison of our patients with patients who had endoscopic
surgery. This was not possible because we do not perform
laparoscopic or robotic myomectomy in our institution.
Our complication rate among patients who had undergone
myomectomy was 19.7%. The risk factors for early and latecomplications of myomectomy have been presented in many
studies, and some risk factors have been evaluated. Pundir et al
found uterine size of 20 gestational weeks or more, previous
abdominal myomectomy and myoma type were associated
with increased complication rates.33 Mettler et al found an
association between the fibroid size, location and increased
complication rates; and Roth et al showed that race was related
to complications in patients who underwent abdominal myo-
mectomy.34,35 In our study, we demonstrated that CA-125
levels, nonsubserosal fibroid location and BMI were signifi-
cantly valuable in predicting complications in patients who
underwent abdominal myomectomy.
In conclusion, the findings of this study showed that
increased BMIwas associatedwith adverse clinical outcomes in
patients who had undergone abdominal myomectomy, either
during or after abdominal myomectomy. Therefore, necessary
precautions should be taken against obesity in all women.
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